Trials / Completed
CompletedNCT02297958
Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 28 (actual)
- Sponsor
- Rennes University Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Ovarian carcinoma has poor prognosis and new therapeutic strategies are required. Many patients with ovarian carcinoma showed resistance to chemotherapy. Cleaved FasL is known for induced atypical response when is binding to Fas such as avoiding apoptosis and inducing cell motility.
Conditions
Timeline
- Start date
- 2015-01-15
- Primary completion
- 2019-07-27
- Completion
- 2019-07-27
- First posted
- 2014-11-21
- Last updated
- 2020-08-31
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02297958. Inclusion in this directory is not an endorsement.